Navigation Links
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
Date:6/18/2013

t of RMB801.8 million ($129.1 million) as of March 31, 2013.  Operating cash inflow for the fourth quarter of fiscal 2013 amounted to RMB155.1 million ($25.0 million), representing a significant growth from RMB102.2 million in the prior year period.

Full Year Fiscal 2013 Financial ResultsFor the full year fiscal year 2013, total revenues increased by 38.3% to RMB526.1 million ($84.7 million) from RMB380.5 million in the prior year.  The increase was largely attributable to the significant increase in new subscribers during the "Dragon Year" baby boom and the expansion of the Company's accumulated subscriber base to 311,982 subscribers.  Similarly, revenues related to processing fees and storage fees grew by 40.9% and 30.8%, respectively.  Gross profit increased by 42.8% to RMB419.5 million ($67.5 million) from RMB293.8 million in the prior year, and operating income increased by 55.2% to RMB209.3 million ($33.7 million) from RMB134.8 million in the prior year. Interest expense increased to RMB70.1 million ($11.3 million) from RMB3.3 million in the prior year, and the increase was largely attributable to the convertible notes issuances during fiscal 2013.  As such, income before income tax grew 4.3% to RMB158.2 million ($25.5 million), from RMB151.6 million in the prior year.  Income tax expense was lower in fiscal 2012 because the Company recorded a tax write-back due to the High and New Technology Enterprise tax status of both Beijing and Guangdong subsidiaries during fiscal 2012, no such write-back was recorded during fiscal 2013. Combining the effects of higher interest expense and lack of tax write-back in fiscal 2013, net income attributable to the Company for the fiscal 2013 amounted to RMB112.4 million ($18.1 million).  Basic and diluted earnings per share attributable to ordinary shares were RMB1.49 ($0.24).  The calculation of basic and diluted earnings per share has taken into consideration the effect of the
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. RAPS Opens Offices in Singapore and China
2. Research Report on Chinas Diabetes Drug Market, 2013-2017
3. Research Report on Chinas Antidepressant Market, 2013-2017
4. Research Report on Chinas Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
6. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
7. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
8. China Engineering Plastics Industry will Reach US$5 Million By 2017 - Engineering Plastics Market, Share, Size, Analysis, Market Scale, Competition and Forecast 2013-2017
9. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
10. Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted
11. China Cord Blood Corporation Received AABB Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Navitas Life Sciences is delighted ... Head of Clinical and Regulatory Services. Shalabh is a proven ... co-founder and CEO of Kinapse, as well as a Strategy ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... commented "I am delighted to welcome Shalabh into this ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... platform company serving the pharmaceutical, biotechnology and medical device ... and the United States , today ... first quarter of 2015 after the New York Stock ... be Thursday morning, May 14, 2015 Shanghai time). The ...
(Date:4/23/2015)... 23, 2015 Glemser Technologies ... first EMC® Enterprise Content Division (ECD) Certified Solution ... EMC Documentum® for Life Sciences Solution Suite . ... and capabilities to provide life sciences companies of ... , The EMC Documentum Solution Suite offers four ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Firmenich,s world leadership in the ... flavor ingredients, - New S2383 flavor enhancer may be used in ... healthcare products to reduce the need for sucralose, ... Inc. (Nasdaq: SNMX ), a leading company,focused on using proprietary ...
... BOSTON, Nov. 6 Solos Endoscopy, Inc. (Pink,Sheets: SNDY) ... a,significant purchase order for laparoscopic instruments from the St. ... client of Solos,Endoscopy,s for over 19 yrs and it ... Saint Mary,s Hospital has played a vital role in ...
... Inc. (NTI(R)) (Nasdaq: NTII ) today announced its ... first quarter of the,company,s fiscal year ending June 30, ... was $3.6 million, compared to $3.9 million for the,three ... million,for the first quarter of fiscal 2009 compared to ...
Cached Biology Technology:SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 3Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 4Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 5
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... After a year of studying up close the symbiotic relationship ... University biologist has advanced the scientific understanding of biological diversity. ... relationship between two or more organisms that can be parasitic ... diversity as predation and competition. The Proceedings ...
... , Feb. 5, 2013 Reportlinker.com ... is available in its catalogue: ... and Prognostic Biomarkers, 2013 ... Endothelial Growth Factor (VEGF), which plays an ...
... When it comes to gene sequencing and personalized medicine for ... proteins are relatively easy to target with drugs and plenty ... study, University of Michigan Comprehensive Cancer Center researchers assess the ... kinases are acting up in a particular tumor. They go ...
Cached Biology News:Pirate-like flies connect symbiosis to diversity 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 3VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 4VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 5Study finds potential to match tumors with known cancer drugs 2Study finds potential to match tumors with known cancer drugs 3
... Monoclonal to L1 Cell Adhesion Molecule ... located in Xq28, is involved in three ... aqueduct of Sylvius); 2) MASA (mental retardation, ... SPG1 (spastic paraplegia). Immunogen: ...
...
... The Beacon 2000 One-Step FP Standardization ... high and low fluorescence polarization values ... of the Beacon 2000 System. It ... polarization values generated by their instrument ...
... Engineered with new technology incorporating ... for unsurpassed flexibility, the new Varian ... advanced spectrometer available today., ,The Varian ... each transmitter and receiver channel, providing ...
Biology Products: